<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301325</url>
  </required_header>
  <id_info>
    <org_study_id>U54 DA031659-P1S2</org_study_id>
    <secondary_id>1U54DA031659-01</secondary_id>
    <nct_id>NCT02301325</nct_id>
  </id_info>
  <brief_title>Project 1, Study 2: The Combined Impact of Nicotine Replacement and Spectrum Cigarettes</brief_title>
  <official_title>Project 1, Study 2: The Combined Impact of Nicotine Replacement and Spectrum Cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Project 1, Study 2 will evaluate the impact of very low nicotine content cigarettes with and&#xD;
      without transdermal nicotine on cigarettes smoked per day, nicotine exposure,&#xD;
      discomfort/dysfunction, other health-related behaviors, nicotine/tobacco dependence,&#xD;
      biomarkers of tobacco exposure, intention to quit, compensatory smoking, other tobacco use,&#xD;
      cigarette characteristics, cue reactivity, cardiovascular function, perceived risk and cue&#xD;
      reactivity. The investigators will also consider differences between conditions in compliance&#xD;
      with product use and the ability to abstain from smoking when provided a financial incentive&#xD;
      for abstinence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cigarettes Smoked Per Day</measure>
    <time_frame>Six Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Cigarette Smoking</condition>
  <arm_group>
    <arm_group_label>0.03 mg Nicotine Cigarette</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.03 mg Nicotine Cigarette and NRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes and use nicotine replacement patches.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.80 mg Nicotine Cigarette</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.80 mg Nicotine Cigarette and NRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes and use nicotine replacement patches.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smoking research cigarettes with or without NRT</intervention_name>
    <arm_group_label>0.03 mg Nicotine Cigarette</arm_group_label>
    <arm_group_label>0.03 mg Nicotine Cigarette and NRT</arm_group_label>
    <arm_group_label>0.80 mg Nicotine Cigarette</arm_group_label>
    <arm_group_label>0.80 mg Nicotine Cigarette and NRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18+&#xD;
&#xD;
          2. Smoke an average of at least five cigarettes per day for the last year with no periods&#xD;
             of continuous abstinence longer than 30 days.&#xD;
&#xD;
          3. Breath CO levels &gt; or = 10 ppm (if &lt; 10 ppm, then NicAlert Strip = 6)&#xD;
&#xD;
          4. Fulfills need for participants in the required strata (menthol status)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intention to quit smoking in the next 30 days&#xD;
&#xD;
          2. Currently seeking treatment for smoking cessation&#xD;
&#xD;
          3. Currently using nicotine replacement therapies or other pharmacotherapies as cessation&#xD;
             aid (intermittent use acceptable)&#xD;
&#xD;
          4. Significant prior adverse reaction to nicotine replacement as determined by the&#xD;
             licensed medical professional.&#xD;
&#xD;
          5. A quit attempt in the past 30 days resulting in greater than 3 days of abstinence&#xD;
&#xD;
          6. Using other tobacco products more than 9 days in the past 30 days&#xD;
&#xD;
          7. Significant unstable medical conditions (any significant change in a serious medical&#xD;
             condition occurring during the past 3 months including cardiovascular disease, COPD,&#xD;
             and cancer, as determined by the licensed medical professional)&#xD;
&#xD;
          8. Significant unstable psychiatric conditions (any significant change in psychiatric&#xD;
             symptoms during the past 3 months as determined by the licensed medical professional)&#xD;
&#xD;
          9. Schizophrenia and schizoaffective disorder&#xD;
&#xD;
         10. Positive toxicology screen for any of the following drugs: marijuana, cocaine,&#xD;
             opiates, methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and&#xD;
             PCP&#xD;
&#xD;
               -  Participants with valid prescriptions for any toxicology results will not be&#xD;
                  excluded.&#xD;
&#xD;
         11. Breath alcohol level &gt; 0.01&#xD;
&#xD;
         12. Binge drinking alcohol (more than 9 days in the past 30 days, 4/5 drinks in a 2 hour&#xD;
             period (female/male))&#xD;
&#xD;
         13. Pregnant, trying to become pregnant or breastfeeding&#xD;
&#xD;
         14. Smoking 'roll your own cigarettes' exclusively&#xD;
&#xD;
         15. Currently taking any one of the following medications:&#xD;
&#xD;
               -  Phenytoin [Brand Name: Dilantin]&#xD;
&#xD;
               -  Carbamazepine [Brand Name: Tegretol, Carbatrol, Equetro, Epitol]&#xD;
&#xD;
               -  Oxcarbazepine [Brand Name: Trileptal]&#xD;
&#xD;
               -  Primidone [Brand Name: Mysoline]&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Bendamustine [Brand Name: Treanda]&#xD;
&#xD;
               -  Clopidogrel [Brand Name: Plavix]&#xD;
&#xD;
               -  Clozapine [Brand Name: Clozaril, FazaClo]&#xD;
&#xD;
               -  Erlotinib [Brand Name: Tarceva]&#xD;
&#xD;
               -  Flecainide [Brand Name: Tambocor]&#xD;
&#xD;
               -  Fluvoxamine [Brand Name: Luvox]&#xD;
&#xD;
               -  Irinotecan [Brand Name: Camptosar]&#xD;
&#xD;
               -  Olanzapine [Brand Name: Zyprexa]&#xD;
&#xD;
               -  Ropinirole [Brand Name: Requip]&#xD;
&#xD;
               -  Tacrine [Brand Name: Cognex]&#xD;
&#xD;
               -  Theophylline [Brand Name: Theo Dur]&#xD;
&#xD;
               -  Estradiol&#xD;
&#xD;
         16. CO reading &gt;80 ppm&#xD;
&#xD;
         17. Systolic BP greater than or equal to 160&#xD;
&#xD;
               -  Participants failing for blood pressure will be allowed to re-screen once.&#xD;
&#xD;
         18. Diastolic BP greater than or equal to 100&#xD;
&#xD;
               -  Participants failing for blood pressure will be allowed to re-screen once.&#xD;
&#xD;
         19. Systolic BP below 90&#xD;
&#xD;
               -  Participants failing for blood pressure will be allowed to re-screen once.&#xD;
&#xD;
         20. Diastolic BP below 50&#xD;
&#xD;
               -  Participants failing for blood pressure will be allowed to re-screen once.&#xD;
&#xD;
         21. Heart rate greater than or equal to 105 bpm&#xD;
&#xD;
               -  Participants failing for heart rate will be allowed to re-screen once.&#xD;
&#xD;
         22. Heart rate lower than 45 bpm&#xD;
&#xD;
               -  Participants failing for heart rate will be allowed to re-screen once.&#xD;
&#xD;
         23. Indicating any suicidal ideation in the past month or suicide attempts in the past 5&#xD;
             years (if within the past 6-10 years, LMP approval required).&#xD;
&#xD;
         24. Inability to independently read and comprehend the consent form and other written&#xD;
             study materials and measures.&#xD;
&#xD;
         25. Having participated in a research study during the past three months in which the&#xD;
             participant:&#xD;
&#xD;
               -  Smoked a cigarette that was not his/her usual brand cigarette for more than one&#xD;
                  day&#xD;
&#xD;
               -  Used any tobacco products beyond normal use for more than one day&#xD;
&#xD;
               -  Used any nicotine replacement products or smoking cessation medications for more&#xD;
                  than one day&#xD;
&#xD;
         26. Having participated in Project 1, Study 1 (PRO11060292)&#xD;
&#xD;
         27. Having participated in Project 1, Study 1C (PRO14040384)&#xD;
&#xD;
         28. Household member enrolled in the study concurrently&#xD;
&#xD;
         29. Significant prior adverse reactions to adhesives or latex&#xD;
&#xD;
         30. Participant has a condition that interferes/does not allow for the collection of&#xD;
             eligibility criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Donny, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2014</study_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

